Published in

Massachusetts Medical Society, New England Journal of Medicine, 14(363), p. 1313-1323, 2010

DOI: 10.1056/nejmoa1001527

Elsevier, Year Book of Pediatrics, (2012), p. 483-484

DOI: 10.1016/j.yped.2011.04.023

Links

Tools

Export citation

Search in Google Scholar

Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

Journal article published in 2010 by David L. Baker, A. Thomas Look, Mary L. Schmidt, Susan L. Cohn, John M. Maris, Wendy B. London, Allen Buxton, Daniel Stram, Robert P. Castleberry, Hiroyuki Shimada, Anthony Sandler, Robert C. Shamberger, A. Thomas Look, C. Patrick Reynolds ORCID, Robert C. Seeger and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background The survival rate among patients with intermediate-risk neuroblastoma who receivedose-intensive chemotherapy is excellent, but the survival rate among patients whoreceive reduced doses of chemotherapy for shorter periods of time is not known.MethodsWe conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology−based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (